SCHEMBL6108340

SCHEMBL6108340

CCc1cc(C)cc2nc(Nc3ccc(-c4cn([C@H]5CC[C@@H](N6CCN(C)CC6)CC5)c5ncnc(N)c45)cc3F)oc12

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 9/20 0.84
ERBB2 P04626 9/20 0.84
ERBB4 Q15303 9/20 0.84
IGF1R P08069 8/20 0.84
ERBB3 P21860 8/20 0.84
TEK Q02763 2/20 0.51
NEK7 Q8TDX7 10/20 0.50
PLK4 O00444 1/20 0.50
DCLK1 O15075 1/20 0.50
PDPK1 O15530 1/20 0.50
PRKD3 O94806 1/20 0.50
MAP4K4 O95819 1/20 0.50
PAK4 O96013 1/20 0.50
CHEK2 O96017 1/20 0.50
ABL1 P00519 1/20 0.50
NTRK1 P04629 1/20 0.50
INSR P06213 1/20 0.50
LCK P06239 1/20 0.50
FYN P06241 1/20 0.50
CSF1R P07333 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3822288 1.00 EGFR (0.84) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL6107989 0.91 EGFR (1.00) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL6107993 0.91 EGFR (1.00) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL3818589 0.90 EGFR (0.82) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL6108958 0.90 EGFR (0.82) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL3821053 0.86 EGFR (0.74) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL6108420 0.86 EGFR (0.74) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL6109588 0.85 EGFR (0.75) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL6109590 0.85 EGFR (0.75) EGFRERBB2ERBB4IGF1RERBB3
SCHEMBL6867295 0.85 EGFR (0.75) EGFRERBB2ERBB4IGF1RERBB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABBOTT LABORATORIES 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025383-A1 Aminobenzoxazoles as therapeutic agents ABL1, MAP3K19, MAP3K20 EGFR 506/4885ERBB2 47/4885ERBB4 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.